Ustekinumab Dawns: Surveying The Biosimilar Landscape For IBD
Who’s Doing What In The IBD Space After IL-12/IL-23 Competition Opens Up
Biologic treatments for inflammatory bowel disease, Crohn’s disease and ulcerative colitis, are growing apace in Europe, buoyed by biosimilar competition for the first wave of treatments like infliximab and adalimumab. Generics Bulletin looks at what is on the horizon in the growing, multi-billion-dollar IBD space.
